The November 15 Clinical Cancer Research includes a comprehensive review of a technology called molecular imaging probes and their use in the development of cancer drugs. The article, "The Progress and Promise of Molecular Imaging Probes in Oncologic Drug Development," is the second in a series of publications written by members of the NCI-FDA IOTF. The authors review the state of the science, discuss clinical applications of imaging probes, and make recommendations for advancing the field in the future. The first article in the IOTF series, "Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development," appeared in the April 15 Clinical Cancer Research.
Workshop Addresses Cancer Health Disparities
Dr. Mark Clanton, deputy director, NCI, and deputy director for Cancer Care Delivery Systems, remarked that the gathering was another important step toward reducing cancer health disparities, which was recently named one of NCI's seven strategic priorities for reaching the 2015 challenge goal.
Dr. John Niederhuber, deputy director, NCI, and deputy director for Translational and Clinical Sciences, added that "we will not be able to meet those challenges down the road, unless we first solve this crucial issue along the way." He predicted that, in just the next decade, the face of medicine will change dramatically, mediated by new technologies for screening, detection, and genomics. "If we don't figure out how to translate this new era to these special populations, they will be left even further behind. It's a challenge we have to meet…and we will," he said.
Teleconference Focuses on NIH Clinical Center
This teleconference will focus on the NIH Clinical Center and describe how cancer patients participate in clinical research to find new treatments for cancer at NIH's world-renowned research hospital.
Dr. John Gallin, director of the NIH Clinical Center; Dottie Cirelli, Clinical Center patient recruitment coordinator; and Susan Lowell Butler, patient advocate; will discuss clinical trials at NCI. A question and answer session will follow the panelists' presentations.
The "Understanding NCI" teleconference series is sponsored by the NCI Office of Liaison Activities. For additional information, go to http://la.cancer.gov.
Since its debut in January 2004, the NCI Cancer Bulletin has provided its readers with a weekly roundup of news from the cancer community - from research highlights to clinical trials to community updates. From December 1-22, you'll have the opportunity to tell us how we're doing by completing an online reader survey.
By completing this short questionnaire, you'll help us to better meet the needs of our readers. Your feedback is vital in shaping future issues of the Bulletin.
All survey responses are confidential and respondents can choose to answer or skip any questions in the survey. For more information, please contact Nina Goodman at email@example.com or 301-435-7789.
Special Issue on NCI Training Opportunities